SON NGUYEN: Open Payments
NPI 1710121348 · GRETNA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$745 in 35 payments from 12 companies in 2025. Trend: 2023 $754 · 2024 $725 · 2025 $745
Food & beverage: $745
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $171 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $137 |
| Novo Nordisk Inc | 5 | $96 |
| GlaxoSmithKline, LLC. | 4 | $80 |
| Gilead Sciences, Inc. | 3 | $77 |
| Amgen Inc. | 3 | $43 |
| Indivior Inc. | 1 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $19 |
Products named: JARDIANCE, BREZTRI, FARXIGA, Rybelsus, OTEZLA, TRELEGY ELLIPTA, SUBLOCADE, SHINGRIX.
Industry payments across LA — which companies pay providers there.
